Rational design of antirheumatic prodrugs specific for sites of inflammation.

ABSTRACT:

Objective

Biologic drugs, such as the anti-tumor necrosis factor (anti-TNF) antibody adalimumab, have represented a breakthrough in the treatment of rheumatoid arthritis. Yet, concerns remain over their lack of efficacy in a sizable proportion of patients and their potential for systemic side effects such as infection. Improved biologic prodrugs specifically targeted to the site of inflammation have the potential to alleviate current concerns surrounding biologic anticytokine therapies. The purpose of this study was to design, construct, and evaluate in vitro and ex vivo the targeting and antiinflammatory capacity of activatable bispecific antibodies.

Methods

Activatable dual variable domain (aDVD) antibodies were designed and constructed to target intercellular adhesion mol

SUBMITTER: Onuoha SC 

PROVIDER: S-EPMC4832285 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature